Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912342925> ?p ?o ?g. }
- W2912342925 endingPage "373" @default.
- W2912342925 startingPage "365" @default.
- W2912342925 abstract "Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next-generation sequencing in the context of clinical practice. Our aim is to rank the level of evidence of individual recurrent genomic alterations observed in breast cancer based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in order to help the clinicians to prioritize treatment. Analyses of databases suggested that there are around 40 recurrent driver alterations in breast cancer. ERBB2 amplification, germline BRCA1/2 mutations, PIK3CA mutations were classified tier of evidence IA based on large randomized trials showing antitumor activity of targeted therapies in patients presenting the alterations. NTRK fusions and microsatellite instability (MSI) were ranked IC. ESR1 mutations and PTEN loss were ranked tier IIA, and ERBB2 mutations and AKT1 mutations tier IIB. Somatic BRCA 1/2 mutations, MDM2 amplifications and ERBB 3 mutations were ranked tier III. Seventeen genes were ranked tier IV based on preclinical evidence. Finally, FGFR1 and CCND1 were ranked tier X alterations because previous studies have shown lack of actionability." @default.
- W2912342925 created "2019-02-21" @default.
- W2912342925 creator A5005295243 @default.
- W2912342925 creator A5025554206 @default.
- W2912342925 creator A5032785430 @default.
- W2912342925 creator A5033409542 @default.
- W2912342925 creator A5037964830 @default.
- W2912342925 creator A5041145711 @default.
- W2912342925 creator A5041410352 @default.
- W2912342925 creator A5049463190 @default.
- W2912342925 creator A5051629490 @default.
- W2912342925 creator A5056844302 @default.
- W2912342925 creator A5057182996 @default.
- W2912342925 creator A5057269336 @default.
- W2912342925 creator A5060044961 @default.
- W2912342925 creator A5082195410 @default.
- W2912342925 creator A5087308492 @default.
- W2912342925 creator A5087559224 @default.
- W2912342925 date "2019-03-01" @default.
- W2912342925 modified "2023-10-14" @default.
- W2912342925 title "Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)" @default.
- W2912342925 cites W1516684943 @default.
- W2912342925 cites W1861759122 @default.
- W2912342925 cites W1940241680 @default.
- W2912342925 cites W2011911766 @default.
- W2912342925 cites W2028846884 @default.
- W2912342925 cites W2033779255 @default.
- W2912342925 cites W2048122601 @default.
- W2912342925 cites W2070727336 @default.
- W2912342925 cites W2076865561 @default.
- W2912342925 cites W2096283457 @default.
- W2912342925 cites W2097255042 @default.
- W2912342925 cites W2100374586 @default.
- W2912342925 cites W2104287359 @default.
- W2912342925 cites W2121906867 @default.
- W2912342925 cites W2132230893 @default.
- W2912342925 cites W2141766988 @default.
- W2912342925 cites W2144790402 @default.
- W2912342925 cites W2146384083 @default.
- W2912342925 cites W2167179525 @default.
- W2912342925 cites W2335155752 @default.
- W2912342925 cites W2382439592 @default.
- W2912342925 cites W2409987903 @default.
- W2912342925 cites W2415372857 @default.
- W2912342925 cites W2528767298 @default.
- W2912342925 cites W2536094308 @default.
- W2912342925 cites W2550856922 @default.
- W2912342925 cites W2552099557 @default.
- W2912342925 cites W2561432266 @default.
- W2912342925 cites W2570752636 @default.
- W2912342925 cites W2580220347 @default.
- W2912342925 cites W2587775236 @default.
- W2912342925 cites W2588750958 @default.
- W2912342925 cites W2601520864 @default.
- W2912342925 cites W2613226689 @default.
- W2912342925 cites W2621271973 @default.
- W2912342925 cites W2726739357 @default.
- W2912342925 cites W2740934820 @default.
- W2912342925 cites W2745136073 @default.
- W2912342925 cites W2764292139 @default.
- W2912342925 cites W2766810628 @default.
- W2912342925 cites W2784814401 @default.
- W2912342925 cites W2785610956 @default.
- W2912342925 cites W2788733333 @default.
- W2912342925 cites W2790254562 @default.
- W2912342925 cites W2790943290 @default.
- W2912342925 cites W2804853604 @default.
- W2912342925 cites W2886477543 @default.
- W2912342925 cites W2888034354 @default.
- W2912342925 cites W2890084166 @default.
- W2912342925 cites W2951449583 @default.
- W2912342925 cites W2953390364 @default.
- W2912342925 doi "https://doi.org/10.1093/annonc/mdz036" @default.
- W2912342925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30715161" @default.
- W2912342925 hasPublicationYear "2019" @default.
- W2912342925 type Work @default.
- W2912342925 sameAs 2912342925 @default.
- W2912342925 citedByCount "93" @default.
- W2912342925 countsByYear W29123429252019 @default.
- W2912342925 countsByYear W29123429252020 @default.
- W2912342925 countsByYear W29123429252021 @default.
- W2912342925 countsByYear W29123429252022 @default.
- W2912342925 countsByYear W29123429252023 @default.
- W2912342925 crossrefType "journal-article" @default.
- W2912342925 hasAuthorship W2912342925A5005295243 @default.
- W2912342925 hasAuthorship W2912342925A5025554206 @default.
- W2912342925 hasAuthorship W2912342925A5032785430 @default.
- W2912342925 hasAuthorship W2912342925A5033409542 @default.
- W2912342925 hasAuthorship W2912342925A5037964830 @default.
- W2912342925 hasAuthorship W2912342925A5041145711 @default.
- W2912342925 hasAuthorship W2912342925A5041410352 @default.
- W2912342925 hasAuthorship W2912342925A5049463190 @default.
- W2912342925 hasAuthorship W2912342925A5051629490 @default.
- W2912342925 hasAuthorship W2912342925A5056844302 @default.
- W2912342925 hasAuthorship W2912342925A5057182996 @default.
- W2912342925 hasAuthorship W2912342925A5057269336 @default.
- W2912342925 hasAuthorship W2912342925A5060044961 @default.
- W2912342925 hasAuthorship W2912342925A5082195410 @default.